EUVIMEDEUVIMED entdecken
Open Access

A novel nuclear RNA HSD52 scaffolding NONO/SFPQ complex modulates DNA damage repair to facilitate temozolomide resistance

Nan Sun, Qun Chen, Hao Chen, Penggang Sun, Yuxiang Liu, Dan Song, Daohan Yu, Pandeng Wang, Yu Song, Jie Qin, Kaifu Tian, Junzhe Zhong und 9 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Nan Sun und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: Temozolomide, Drug Resistance, Neoplasm, DNA Repair, Brain Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Heilongjiang Provincial Key R & D Project, Harbin Medical University Marshal Initiative Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Temozolomide (TMZ) is used in the treatment of glioblastoma (GBM). However, the primary obstacle remains the emergence of TMZ chemotherapy resistance. Non-POU domain-containing octamer-binding protein (NONO) and splicing factor proline/glutamine rich (SFPQ) are multifunctional nuclear proteins involved in genome stability and gene regulation. However, the specific role of NONO and SFPQ in TMZ resistance of GBM remains to be explored.

Methods

RNA-binding protein immunoprecipitation-microarray and RNA microarray of TMZ-resistant and parental cells were performed for the gain of HSD52. The effects of HSD52 on TMZ resistance were investigated through in vitro assays, intracranial xenograft, and GBM organoid models. The underlying mechanisms were explored by DNA methylation chip, RNA immunoprecipitation, RNA pull-down assays, among others. GBM clinical samples were rolled in to investigate the clinical significance of HSD52.

Results

We identified a novel noncoding RNA, HSD52, that was highly expressed in TMZ-resistant GBM and facilitated the interaction between NONO and SFPQ. H3 ubiquitination attenuation and reduced DNA methyltransferase 1 (DNMT1) recruitment increased HSD52 transcription via DNA hypo-methylation. HSD52 formed an RNA duplex with UFM1 specific ligase 1 (UFL1) mRNA, thereby promoting NONO/SFPQ complex binding to UFL1 mRNA and enhancing its stability, and then contributed to TMZ resistance through activating the ataxia telangiectasia mutated signaling pathway. In vivo xenograft and GBM organoid models showed significant repression in tumor growth after HSD52 knockout with TMZ treatment. In GBM clinical samples, HSD52 was responsible for the malignant progression and TMZ resistance.

Conclusions

Our results revealed that HSD52 could serve as a promising therapeutic target to overcome TMZ resistance, improving the clinical efficacy of TMZ chemotherapy in GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideDrug Resistance, NeoplasmDNA RepairBrain NeoplasmsGlioblastomaRNA-Binding ProteinsPTB-Associated Splicing FactorHumansAnimalsMiceAntineoplastic Agents, AlkylatingXenograft Model Antitumor AssaysMice, NudeTumor Cells, CulturedGene Expression Regulation, NeoplasticCell ProliferationDNA DamageDNA MethylationCell Line, TumorDNA-Binding Proteins

Stichwörter der Autor:innen

DNA damage repair | glioblastoma | HSD52NONO/SFPQ complextemozolomide resistance

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingNONO protein, humanRNA-Binding ProteinsPTB-Associated Splicing FactorDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Future Medical Laboratory, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Department of Burn and Plastic Surgery-Hand Surgery, Changshu Hospital Affiliated to Soochow University, Changshu No.1 People's Hospital, Changshu, China.
  • Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wu Lien-Teh Biomedical Innovation Institute, The Sixth Affiliated Hospital of Harbin Medical University, Harbin, China.

Förderung

  • National Natural Science Foundation of China
  • Heilongjiang Provincial Key R & D Project
  • Harbin Medical University Marshal Initiative Funding
  • China Postdoctoral Science Foundation
  • ural Science Foundation of Heilongjiang Province
  • Medjaden Academy & Research Foundation for Young Scientists
  • ealth China BuChang ZhiYuan Pubic Welfare Project for Heart and Brain Health

Zitieren

APA

Sun, N., Chen, Q., Chen, H., Sun, P., Liu, Y., Song, D., Yu, D., Wang, P., Song, Y., Qin, J., Tian, K., Zhong, J., Ma, W., Xuan, H., Qian, D., Yuan, Y., Chen, T., Wang, X., Jiang, C., …, & Meng, X. (2025). A novel nuclear RNA HSD52 scaffolding NONO/SFPQ complex modulates DNA damage repair to facilitate temozolomide resistance. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae272

Vancouver

Sun N, Chen Q, Chen H, Sun P, Liu Y, Song D, et al. A novel nuclear RNA HSD52 scaffolding NONO/SFPQ complex modulates DNA damage repair to facilitate temozolomide resistance. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae272

BibTeX
@article{Sun2025,
  author = {Sun, Nan and Chen, Qun and Chen, Hao and Sun, Penggang and Liu, Yuxiang and Song, Dan and Yu, Daohan and Wang, Pandeng and Song, Yu and Qin, Jie and Tian, Kaifu and Zhong, Junzhe and Ma, Wenbin and Xuan, Hanwen and Qian, Da and Yuan, Ye and Chen, Tongzheng and Wang, Xin and Jiang, Chuanlu and Cai, Jinquan and Meng, Xiangqi},
  title = {A novel nuclear RNA HSD52 scaffolding NONO/SFPQ complex modulates DNA damage repair to facilitate temozolomide resistance},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae272}
}
Kostenlos starten →